natgillin/translations-raw huggingface dataset:
In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of &lt; 50 ml/min (see section 4.2).
Farmakokinetički profil lamivudina u starijih bolesnika pokazuje da smanjenje funkcije bubrega uslijed normalnog procesa starenja nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina &lt; 50 ml/min (vidjeti dio 4.2).
In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of &lt; 50 ml/min.
U starijih bolesnika normalno starenje praćeno slabljenjem bubrežne funkcije nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina &lt; 50 ml/min.
In ferrets, lomitapide was both maternally toxic and teratogenic at &lt; 1 times the MRHD.
U tvorova lomitapid je bio i maternalno toksičan i teratogen pri dozi &lt; 1 puta većoj od maksimalne preporučene doze u ljudi.
In four patients &lt; 1 year of age, the overall safety profile of a higher dose (2 mg/kg/week) did not differ in a clinically meaningful manner from that of the recommended 1 mg/kg/week dose, and was consistent with the safety profile of Naglazyme in older children.
U četiri bolesnika mlađih od godinu dana, ukupni profil sigurnosti veće doze (2 mg/kg/tjedan) se nije razlikovao značajno u kliničkom smislu od onoga pri preporučenoj dozi od 1 mg/kg/tjedan, i bio je u skladu s profilom sigurnosti Naglazymea kod starije djece.
In general, a body weight &lt; 60 kg is a risk factor for bleeding.
Općenito je tjelesna težina &lt; 60 kg faktor rizika za krvarenje.
In general, at therapeutic doses, detection of intact orlistat in plasma was sporadic and concentrations were extremely low ( &lt; 10 ng/ml or 0.02 µmol), with no evidence of accumulation, which is consistent with minimal absorption.
Općenito, pri terapijskim dozama je pojava nepromijenjenog orlistat u plazmi bila sporadična, i u iznimno malim koncentracijama ( &lt; 10 ng/ml ili 0,02 mol), bez znakova nakupljanja, što je u skladu s minimalnom apsorpcijom.
In general, at therapeutic doses, detection of intact orlistat in plasma was sporadic and concentrations were extremely low ( &lt; 10 ng/ml or 0.02 µmol), with no evidence of accumulation, which is consistent with minimal absorption.
Općenito pri terapijskim se dozama orlistat u plazmi mogao dokazati samo sporadično i u krajnje niskim koncentracijama ( &lt; 10 ng/ml ili 0,02 µmol), bez znakova nakupljanja, što je u skladu s njegovom minimalnom apsorpcijom.
In general, canagliflozin produced clinically and statistically significant (p &lt; 0.001) results relative to placebo in glycaemic control, including glycosylated haemoglobin (HbA1c), the percentage of patients achieving HbA1c &lt; 7%, change from baseline fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG).
Općenito, kanagliflozin je imao klinički i statistički značajne (p &lt; 0,001) rezultate u odnosu na placebo u regulaciji glikemije, uključujući HbA1c, postotak bolesnika koji su postigli glikozilirani hemoglobin (HbA1c), &lt; 7%, promjenu u odnosu na početnu vrijednost glukoze u plazmi natašte (FPG) i 2-satne postprandijalne glukoze (PPG).
In general, canagliflozin produced clinically and statistically significant (p &lt; 0.001) results relative to placebo in glycaemic control, including HbA1c, the percentage of patients achieving HbA1c &lt; 7%, change from baseline fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG).
Općenito, kanagliflozin je imao klinički i statistički značajne (p &lt; 0,001) rezultate u odnosu na placebo u regulaciji glikemije, uključujući HbA1c, postotak bolesnika koji su postigli HbA1c &lt; 7%, promjenu u odnosu na početnu vrijednost glukoze u plazmi natašte (FPG) i 2-satne postprandijalne glukoze (PPG).
In general, elvitegravir pharmacokinetics in paediatric patients (12 to &lt; 18 years of age) and emtricitabine pharmacokinetics in children (aged 4 months to 18 years of age) are similar to those seen in adults.
Općenito, farmakokinetika elvitegravira u pedijatrijskih pacijenata (od 12 do &lt; 18 godina) i farmakokinetika emtricitabina u djece (od 4 mjeseca do 18 godina) slične su farmakokinetici koja se opaža u odraslih osoba.
In general, exposures tended to be higher in the older patients (7 to &lt; 18 years) than in younger patients (2 to &lt; 7 years).
Općenito, izloženost lijeku bila je veća u starijih bolesnika (u dobi od 7 do &lt; 18 godina) nego u mlađih bolesnika (u dobi od 2 do &lt; 7 godina).
In genotype 4, amino acid substitutions at 30 and 93 (EC50 &lt; 16 nM) were frequently selected.
Kod genotipa 4 često su se izdvajale aminokiselinske supstitucije na položajima 30 i 93 (EC50 &lt; 16 nM).
In HBeAg-negative patients with HBV DNA &lt; 300 copies/ml at week 24, resistance was 0% (0/177) at 48 weeks and 5% (9/177) at week 104, whilst in patients with HBV DNA
U HBeAg-negativnih bolesnika s HBV DNK &lt; 300 kopija/ml u 24. tjednu, rezistencija je bila 0% (0/177) u 48. tjednu i 5% (9/177) u 104. tjednu, dok je u bolesnika s HBV DNK
In healthy volunteers, pasireotide intramuscular use is widely distributed with large apparent volume of distribution (Vz/F &gt; 100 litres).
U zdravih dobrovoljaca pasireotid primijenjen intramuskularno ima opsežnu distribuciju uz veliki volumen distribucije (Vz/F &gt; 100 litara).
In healthy young adults (25 to 45 years of age), the protein binding of ertapenem decreases, as plasma concentrations increase, from approximately 95 % bound at an approximate plasma concentration of &lt; 50 micrograms/mL to approximately 92 % bound at an approximate plasma concentration of 155 micrograms/mL (average concentration achieved at the end of infusion following 1 g intravenously).
U zdravih mlađih odraslih osoba (u dobi od 25 do 45 godina) vezanje ertapenema na proteine smanjuje se s povećanjem koncentracije u plazmi, i to sa otprilike 95% vezanja pri približnoj koncentraciji od &lt; 50 mikrograma/ml do približno 92% vezanog ertapenema pri koncentraciji od oko 155 mikrograma/ml (prosječna koncentracija postignuta na kraju intravenske infuzije od 1 g).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations &gt; 4-fold higher in PBMCs and &gt; 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida (primijenjenog s emtricitabinom, elvitegravirom i kobicistatom) rezultirala je koncentracijama tenofovirdifosfata &gt; 4 puta većima u PBMC-ovima i &gt; 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg (primijenjenog s emtricitabinom, elvitegravirom i kobicistatom).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide given with emtricitabine, cobicistat and elvitegravir resulted in tenofovir diphosphate concentrations &gt; 4-fold higher in PBMCs and &gt; 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) given with emtricitabine, cobicistat and elvitegravir.
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida primijenjenog s emtricitabinom, kobicistatom i elvitegravirom rezultirala je koncentracijama tenofovirdifosfata za &gt; 4 puta većima u PBMC-ovima i &gt; 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg primijenjenog s emtricitabinom, kobicistatom i elvitegravirom.
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide in Genvoya resulted in tenofovir diphosphate concentrations &gt; 4-fold higher in PBMCs and &gt; 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) in E/C/F/TDF.
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida u lijeku Genvoya rezultira koncentracijama tenofovirdifosfata &gt; 4 puta većima u PBMC-ovima i &gt; 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg u E/C/T/TDF.
In humans, safinamide is almost exclusively eliminated via metabolism (urinary excretion of unchanged safinamide was &lt; 10%) mediated principally through high capacity amidases, that have not yet been characterized.
U ljudi, safinamid se gotovo isključivo eliminira metabolizmom (ekskrecija nepromijenjenog safinamida urinom bila je &lt; 10%) posredovanim prvenstveno amidazama visokog kapaciteta, koje još uvijek nisu okarakterizirane.
In humans, the protein binding of pramipexole is very low ( &lt; 20 %) and the volume of distribution is large (400 l).
U ljudi, vezanje pramipeksola na proteine plazme je vrlo nisko ( &lt; 20%), a volumen distribucije je vrlo velik (400 l).
In humans, the protein binding of pramipexole is very low ( &lt; 20%) and the volume of distribution is large (400 l).
Kod ljudi pramipeksola se u manjoj mjeri veže na proteine ( &lt; 20%), ali ima velik volumen distribucije (400 l).
In humans, the protein binding of pramipexole is very low ( &lt; 20%) and the volume of distribution is large (400 l).
U ljudi se pramipeksol u manjoj mjeri veže na proteine ( &lt; 20%), ali ima velik volumen distribucije (400 l).
In humans, the protein binding of pramipexole is very low ( &lt; 20%) and the volume of distribution is large (400 l).
U ljudi, vezanje pramipeksola na proteine plazme je vrlo nisko ( &lt; 20%), a volumen distribucije je vrlo velik (400 l).
In male rats, anagrelide at oral doses up to 240 mg/kg/day ( &gt; 1000 times a 2mg/day dose, based on body surface area) was found to have no effect on fertility and reproductive performance.
U mužjaka štakora, nađeno je da anagrelid u peroralnim dozama do 240 mg/kg na dan ( &gt; 1000 puta doza od 2 mg na dan, na temelju površine tijela) nema učinka na plodnost i reproduktivnu sposobnost.
In MDS-003, a large proportion of patients with myelodysplastic syndromes achieved transfusion independence ( &gt; 182 days) on lenalidomide 10 mg (58.1%).
U ispitivanju MDS-003, veliki udio bolesnika s mijelodisplastičnim sindromima postigao je neovisnost o transfuziji ( &gt; 182 dana) uz lenalidomid u dozi od 10 mg (58,1%).
In MDS-004, a significant larger proportion of patients with myelodysplastic syndromes achieved the primary endpoint of transfusion independence ( &gt; 182 days) on lenalidomide 10 mg compared with placebo (55.1% vs.
U ispitivanju MDS-004, značajno veći udio bolesnika s mijelodisplastičnim sindromima ostvario je primarni ishod neovisnosti o transfuziji ( &gt; 182 dana) uz lenalidomid u dozi od 10 mg u usporedbi s onima koji su primali placebo (55,1% nasuprot 6,0%).
In mice, a 2-year carcinogenicity study with pravastatin demonstrates at doses of 250 and 500 mg/kg/day ( &gt; 310 times the maximum human mg/kg dose), statistically significant increases in the incidence of hepatocellular carcinomas in males and females, and lung adenomas in females only.
Na miševima 2-godišnje ispitivanje karcinogenosti pravastatina pokazalo je u dozama od 250 i 500 mg/kg/dan ( &gt; 310 puta maksimalne doze za ljude u mg/kg), statistički značajna povećanja incidencije hepatocelularnih karcinoma u mužjaka i ženki, i adenomima pluća samo u ženki.
In monotherapy studies with axitinib (N = 850), haemoptysis was reported in 3.9% of patients; Grade &gt; 3 haemoptysis was reported in 0.5% of patients.
U ispitivanjima aksitiniba u monoterapiji (N = 850) hemoptiza je prijavljena u 3,9% bolesnika; hemoptiza stupnja &gt; 3 prijavljena je u 0,5% bolesnika.
In most cases of severe liver injury, liver dysfunction had an onset within the first 2 months of therapy, and was characterized by a hepatocellular pattern of injury with transaminase elevations &gt; 20xULN, followed by bilirubin increase.
U većini slučajeva teškog oštećenja jetre, disfunkcija jetre nastupila je unutar prva 2 mjeseca terapije i bila je karakterizirana hepatocelularnim obrascem oštećenja s povišenim transaminazama &gt; 20xGGN nakon čega je slijedio porast koncentracije bilirubina.
In naltrexone / bupropion completed clinical studies, where naltrexone hydrochloride daily doses ranged from 16 mg to 48 mg, there were no cases of elevated transaminases &gt; 3x ULN in conjunction with an increase in bilirubin &gt; 2x ULN.
U završenim kliničkim ispitivanjima s naltrekson / bupropionom gdje su dnevne doze naltreksonklorida bile u rasponu od 16 mg do 48 mg, nije bilo slučajeva povišenih transaminaza &gt; 3x GGN povezanih s povećanjem bilirubina &gt; 2x GGN.
In neonates and infants ( &lt; 3 months) receiving caspofungin at 25 mg/m2 daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C1 hr) and caspofungin trough concentration (C24 hr) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily.
U novorođenčadi i dojenčadi ( &lt; 3 mjeseca), koja su primala kaspofungin u dozi od 25 mg/m2 na dan (što odgovara prosječnoj dnevnoj dozi od 2,1 mg/kg), vršna koncentracija kaspofungina (C1 h) i najniža koncentracija kaspofungina (C24 h) nakon višekratnih doza bile su usporedive s onima primijećenima u odraslih koji su primali kaspofungin u dozi od 50 mg na dan.
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC &lt; 0.5 x 109/L) and thrombocytopenia (platelet count
U novodijagnosticiranoj kroničnoj fazi KML-a, neutropenija 4. stupnja (ABN
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC &lt; 0.5 x 109/l) and thrombocytopenia (platelet count &lt; 10 x 109/l) were observed in 3.6% and &lt; 1% of patients, respectively.
U novodijagnosticiranoj kroničnoj fazi KML-a, neutropenija stupnja (ABN &lt; 0,5 x 109/l) i trombocitopenija (broj trombocita &lt; 10 x 109/l) zapažene su u 3,6% odnosno &lt; 1% bolesnika.
In non- smoking individuals with mild (creatinine clearance 80-50 mL/min), moderate (creatinine clearance &lt; 50-30 mL/min) or severe (creatinine clearance &lt; 30 mL/min) renal impairment, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively.
U nepušača s blagim (klirens kreatinina 80-50 ml/min), umjerenim (klirens kreatinina &lt; 50-30 ml/min) ili teškim (klirens kreatinina &lt; 30 ml/min) oštećenjem funkcije bubrega, koncentracije riocigvata u plazmi (AUC) bile su povećane za 53%, 139% odnosno 54%.
In non-HCV-infected subjects with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) who were not on dialysis, elbasvir and grazoprevir AUC values were increased by 86 % and 65 %, respectively, compared to non-HCV-infected subjects with normal renal function (eGFR &gt; 80 mL/min/1.73 m2).
U ispitanika bez infekcije HCV-om koji su imali teško oštećenje funkcije bubrega (eGFR &lt; 30 ml/min/1,73 m2) i nisu bili na dijalizi, vrijednosti AUC elbasvira i grazoprevira povećale su se za 86% odnosno 65% u odnosu na ispitanike bez infekcije HCV-om s normalnom funkcijom bubrega (eGFR &gt; 80 ml/min/1,73 m2).
In non-responder patients re-treated for 48 or 72 weeks, viral suppression at week 12 (undetectable HCV RNA defined as &lt; 50 IU/ml) has been shown to be predictive for sustained virological response.
U bolesnika koji ranije nisu odgovorili na liječenje te se ponovno liječe 48 odnosno 72 tjedna, supresija virusa u 12. tjednu (nemjerljiva razina HCV RNK definirana kao &lt; 50 IU/ml) pokazala se kao prediktivna za trajni virološki odgovor.
In one clinical trial, the incidence of hypertension of grade ≥ 3 was two fold higher in patients aged &gt; 65 years than in the younger age group ( &lt; 65 years).
U jednom je kliničkom ispitivanju incidencija hipertenzije stupnja ≥ 3 bila dvostruko veća u bolesnika starijih od 65 godina nego u mlađoj dobnoj skupini ( &lt; 65 godina).
In one published study, 20 HIV-infected patients with undetectable plasma viral load ( &lt; 200 copies/mL) receiving indinavir 800 mg every 8 hours were switched in an open, cross-over design to indinavir/ritonavir 400/100 mg every 12 hours.
U jednom je objavljenom ispitivanju 20 bolesnika zaraženih HIV-om s nemjerljivim virusnim opterećenjem u plazmi ( &lt; 200 kopija/ml) koji su primali indinavir u dozi od 800 mg svakih 8 sati u sklopu otvorenog, ukriženog ispitivanja prebačeno na liječenje indinavirom/ritonavirom u dozi od 400/100 mg svakih 12 sati.
In order to qualify for enrolment, patients were required to have a platelet count &lt; lower limit of normal range (LLN), evidence of haemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal, without the need for chronic dialysis.
Da bi bili prikladni za uključivanje, bolesnici su morali imati broj trombocita manji od donje granice normalnog raspona (LLN), dokazanu hemolizu kao što je povišenje LDH u serumu te kreatinin u serumu iznad gornje granice normale, bez potrebe za kroničnom dijalizom.
In paediatric patients &lt; 7 yrs of age, 0/7 male patients tested positive for IgG anti-agalsidase alfa antibodies.
U pedijatrijskih bolesnika mlađih od 7 godina, niti jedan od ukupno 7 muških bolesnika nije bio pozitivan na IgG protutijela anti-agalzidaza alfa.
In paediatric patients &gt; 7 yrs of age, 1/16 male patients tested positive for IgG anti-agalsidase alfa antibodies during the study.
U pedijatrijskih bolesnika starijih od 7 godina, 1 od ukupno 16 muških bolesnika imao je pozitivna IgG protutijela anti-agalzidaza alfa tijekom ispitivanja.
In paediatric population, absolute neutrophil counts &lt; 0.5x109/l at a median of 3 days post transplant occurred in 100% of patients and lasted 5 and 18.5 days in autologous and allogeneic transplant respectively.
U pedijatrijskoj populaciji apsolutan broj neutrofila &lt; 0,5x109/l pri medijanu od 3 dana nakon presađivanja pojavio se u 100% bolesnika te se zadržao 5 dana nakon autolognog i 18,5 dana nakon alogenog presađivanja.
In PARADIGM-HF, hyperkalaemia and serum potassium concentrations &gt; 5.4 mmol/l were reported in 11.6% and 19.7% of Entresto-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.
U ispitivanju PARADIGM-HF, hiperkalijemija i koncentracije kalija u serumu &gt; 5.4 mmol/l bile su prijavljene u 11,6% i 19,7% bolesnika liječenih Entrestom, odnosno u 14,0% i 21,1% bolesnika liječenih enalaprilom.
In PARADIGM-HF, hyperkalaemia and serum potassium concentrations &gt; 5.4 mmol/l were reported in 11.6% and 19.7% of Neparvis-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.
U ispitivanju PARADIGM-HF, hiperkalijemija i koncentracije kalija u serumu &gt; 5.4 mmol/l bile su prijavljene u 11,6% i 19,7% bolesnika liječenih Neparvisom, odnosno u 14,0% i 21,1% bolesnika liječenih enalaprilom.
In PARADIGM-HF, hypotension and clinically relevant low systolic blood pressure ( &lt; 90 mmHg and decrease from baseline of &gt; 20 mmHg) were reported in 17.6% and 4.76% of Entresto-treated patients compared with 11.9% and 2.67% of enalapril-treated patients, respectively.
U ispitivanju PARADIGM-HF, hipotenzija i klinički značajan niski sistolički krvni tlak ( &lt; 90 mmHg i smanjenje od početne vrijednosti &gt; 20 mmHg) bili su prijavljeni u 17,6% i 4,76% bolesnika liječenih Entrestom, odnosno u 11,9% i 2,67% bolesnika liječenih enalaprilom.
In PARADIGM-HF, hypotension and clinically relevant low systolic blood pressure ( &lt; 90 mmHg and decrease from baseline of &gt; 20 mmHg) were reported in 17.6% and 4.76% of Neparvis-treated patients compared with 11.9% and 2.67% of enalapril-treated patients, respectively.
U ispitivanju PARADIGM-HF, hipotenzija i klinički značajan niski sistolički krvni tlak ( &lt; 90 mmHg i smanjenje od početne vrijednosti &gt; 20 mmHg) bili su prijavljeni u 17,6% i 4,76% bolesnika liječenih Neparvisom, odnosno u 11,9% i 2,67% bolesnika liječenih enalaprilom.
In particular, if convulsions, seizures, necrotising enterocolitis, symptoms and signs of caffeine withdrawal, medically abnormal decrease in infant weight gain or interactions with other medicines are suspected as being associated with the use of caffeine citrate, these should be reported to &lt; insert local name and address of Chiesi Farmaceutici S.p.A. &gt;
Osobito, ako se sumnja na to da su konvulzije, napadaji, nekrotizirajući enterokolitis, simptomi i znakovi ustezanja kofeina, medicinski neuobičajeno smanjenje dobivanja na tjelesnoj težini dojenčeta ili interakcije s drugim lijekovima povezane s primjenom kofeincitrata, potrebno ih je prijaviti &lt; navesti lokalno ime i adresu tvrtke Chiesi Farmaceutici S.p.A. &gt;
In patients &lt; 5 years of age, the overall safety profile of Vimizim at 2 mg/kg/week was consistent with the safety profile of Vimizim observed in older children.
U bolesnika &lt; 5 godina starosti, cjelokupni sigurnosni profil Vimizima pri 2 mg/kg/tjedno bio je u skladu sa sigurnosnim profilom Vimizima uočenim u starije djece.
In patients &gt; 75 years undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients &lt; 65 years.
U bolesnika starijih od 75 godina kojima je potreban ortopedski zahvat i koji su primali fondaparinuks 2,5 mg jednom na dan, procijenjeni klirens iz plazme bio je 1,2 do 1,4 puta manji nego u bolesnika mlađih od 65 godina.
In patients &gt; 75 years undergoing orthopaedic surgery, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients &lt; 65 years.
U bolesnika starijih od 75 godina kojima je potreban ortopedski zahvat, procijenjeni klirens iz plazme bio je 1,2 do 1,4 puta manji nego u bolesnika mlađih od 65 godina.
In patients aged &gt; 45 years, dyspnoea was reported in 16.4% of simeprevir-treated patients compared to 9.1% in placebo-treated patients (all grades; pooled phase 3).
U bolesnika starijih &gt; 45 godina, dispneja je bila prijavljena u 16,4% bolesnika liječenih simeprevirom u usporedbi s 9,1% bolesnika liječenih placebom (svi stupnjevi; objedinjeno za fazu 3).
In patients assessed for anti-abatacept antibodies after discontinuation of abatacept ( &gt; 42 days after last dose), 103 of 1,888 (5.5%) were seropositive.
Među bolesnicima koji su testirani na antitijela na abatacept nakon prekida liječenja abataceptom ( &gt; 42 dana nakon posljednje doze), seropozitivno je bilo 103 od 1888 ispitanih (5,5%).
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those &gt; 65 years compared to 4.0% in patients less than 65 years.
U bolesnika na inzulinu bez pioglitazona, incidencija srčanog zatajenja bila je 8,2% kod osoba u dobi ≥65 godina, u odnosu na 4,0% u bolesnika mlađih od 65 godina.
In patients receiving Herceptin after completion of adjuvant chemotherapy, the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of Herceptin and a body mass index (BMI) &gt; 25 kg/m2.
U bolesnika koji su Herceptin primali nakon završetka adjuvantne kemoterapije, rizik od disfunkcije srca povezivao se s većom kumulativnom dozom antraciklina primijenjenoga prije početka liječenja lijekom Herceptin te indeksom tjelesne mase (BMI) većim od 25 kg/m2.
In patients scheduled for major elective orthopaedic surgery with a pre-treatment haemoglobin of &gt; 10 to ≤ 13 g/dl, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).
Dokazano je da epoetin alfa u bolesnika predviđenih za veliki elektivni ortopedski kirurški zahvat s razinom hemoglobina od &gt; 10 do ≤ 13 g/dl prije liječenja smanjuje rizik od primanja alogenih transfuzija i ubrzava eritroidni oporavak (povišene razine hemoglobina i hematokrita te broja retikulocita).